In vitro activities of panduratin A against clinical Staphylococcus strains
- PMID: 19651906
- PMCID: PMC2764148
- DOI: 10.1128/AAC.00624-09
In vitro activities of panduratin A against clinical Staphylococcus strains
Abstract
In vitro antistaphylococcal activities of panduratin A, a natural chalcone compound isolated from Kaempferia pandurata Roxb, were compared to those of commonly used antimicrobials against clinical staphylococcal isolates. Panduratin A had a MIC at which 90% of bacteria were inhibited of 1 microg/ml for clinical staphylococcal isolates and generally was more potent than commonly used antimicrobials.
References
-
- Archer, G. L., and M. W. Climo. 2005. Staphylococcus epidermidis and other coagulase negative staphylococci, p. 2352-2362. In G. L. Mandel, J. E. Bennet, and R. Dolin (ed.), Principles and practice of infection disease. Elsevier Churchill Livingston, Philadelphia, PA.
-
- Bannerman, T. L. 2003. Staphylococcus, Micrococcus, and other catalase-positive cocci that grow aerobically, p. 384-404. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 8th ed. ASM Press, Washington, DC.
-
- Clinical and Laboratory Standards Institute. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard M7-A6. CLSI, Wayne, PA.
-
- French, G. L. 2006. Bactericidal agents in the treatment of MRSA infections—the potential role of daptomycin. J. Antimicrob. Chemother. 58:1107-1117. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
